- Home
- ALX vs MDXG Comparison
ALX vs MDXG Comparison
Compare ALX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- MDXG
- Stock Information
- Founded
- ALX 1928
- MDXG 2006
- Country
- ALX United States
- MDXG United States
- Employees
- ALX N/A
- MDXG N/A
- Industry
- ALX Real Estate Investment Trusts
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- MDXG Health Care
- Exchange
- ALX Nasdaq
- MDXG Nasdaq
- Market Cap
- ALX 1.0B
- MDXG 999.9M
- IPO Year
- ALX N/A
- MDXG N/A
- Fundamental
- Price
- ALX $225.94
- MDXG $5.81
- Analyst Decision
- ALX Sell
- MDXG Strong Buy
- Analyst Count
- ALX 1
- MDXG 2
- Target Price
- ALX $125.00
- MDXG $12.50
- AVG Volume (30 Days)
- ALX 55.9K
- MDXG 544.1K
- Earning Date
- ALX 08-04-2025
- MDXG 07-30-2025
- Dividend Yield
- ALX 7.98%
- MDXG N/A
- EPS Growth
- ALX N/A
- MDXG N/A
- EPS
- ALX 7.72
- MDXG 0.27
- Revenue
- ALX $219,892,000.00
- MDXG $352,375,000.00
- Revenue This Year
- ALX N/A
- MDXG $9.55
- Revenue Next Year
- ALX N/A
- MDXG $11.43
- P/E Ratio
- ALX $29.23
- MDXG $21.52
- Revenue Growth
- ALX N/A
- MDXG 5.34
- 52 Week Low
- ALX $184.76
- MDXG $5.47
- 52 Week High
- ALX $251.63
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ALX 54.14
- MDXG 30.41
- Support Level
- ALX $223.62
- MDXG $5.80
- Resistance Level
- ALX $230.06
- MDXG $6.03
- Average True Range (ATR)
- ALX 5.05
- MDXG 0.19
- MACD
- ALX -0.82
- MDXG -0.05
- Stochastic Oscillator
- ALX 46.69
- MDXG 2.47
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.